about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

With record-break­ing mpox vac­cine sales, Bavar­i­an Nordic buys trio of shots from Emer­gent for $270M cash

3 years ago
Deals
Manufacturing

Alex­is Borisy, Zach Wein­berg de­but $520M idea for a new biotech in­vest­ing mod­el

3 years ago
Financing

GSK re­vis­es Covid deal with Vir, pulls out of next-gen work

3 years ago
Deals
R&D

In­cyte says un­der-the-radar JAK in­hibitor clears a high bar for skin dis­or­der

3 years ago
R&D

Sanofi’s R&D chief John Reed makes sur­prise ex­it

3 years ago
People

Top 100 biotech ven­ture in­vestors; Bris­tol My­ers’ IL-12 breakup; Sci­en­tif­ic twist of fate; Track­ing bio­phar­ma ...

3 years ago
Weekly

Eliem CEO ex­its as neu­ro up­start chops head­count, piv­ots to pre­clin­i­cal pro­gram

3 years ago
People
R&D

As­traZeneca snips IL-12 can­di­date from pipeline as it sharp­ens I/O fo­cus

3 years ago
R&D

PhI­II im­plo­sion forces Gala­pa­gos to scrap a fil­ing plan for fil­go­tinib

3 years ago
R&D
Pharma

Swiss rare dis­ease biotech with­draws IPO to up­date its Nas­daq plans

3 years ago
Financing

As clin­i­cal tri­als get more com­plex, soft­ware start­up Faro bags $20M to help vi­su­al­ize them

3 years ago
Financing
Startups

Roche says its C5 in­hibitor aced PhI­II head-to-head tri­als with As­traZeneca’s Soliris

3 years ago
R&D

Ab­b­Vie opens up to big­ger deals as com­pe­ti­tion heats up — re­port; Small ra­dio­phar­ma­ceu­ti­cal play­er goes pub­lic via ...

3 years ago
News Briefing

Astel­las taps chief strat­e­gy of­fi­cer as next CEO to 'go on the ag­gres­sive'

3 years ago
People

The Big Phar­ma dis­card pile; Lay­offs all around while some biotechs bid farewell; New Roche CEO as­sem­bles top team; ...

3 years ago
Weekly

Sanofi scraps PhI­II tri­al for Prin­cip­ia drug af­ter re­view­ing com­pe­ti­tion

3 years ago
R&D
Pharma

Be­hind Fri­day's $161M IPO: A star sci­en­tist, GPCR drug dis­cov­ery and a plan to chal­lenge phar­ma in di­a­betes

3 years ago
Financing

Roche ditch­es fi­nal PhI­II for can­cer hope­ful, re­ports set­back for key drug in $1.4B buy­out

3 years ago
R&D

FDA ap­proves GSK's ane­mia drug with safe­ty warn­ing — af­ter bat­ting back sim­i­lar drugs

3 years ago
Pharma
FDA+

GSK dou­bles down on vac­cines, HIV meds as CEO Em­ma Walm­s­ley touts 'land­mark' 2022

3 years ago
Pharma

Go­ing block­buster hunt­ing, Vas Narasimhan out­lines vi­sion for ‘pure-play’ No­var­tis

3 years ago
Pharma

GSK drops celi­ac drug, an­ti-bac­te­r­i­al vac­cine in lat­est pipeline sweep

3 years ago
R&D

Up­dat­ed: No­var­tis re­jigs late-stage plans for Cosen­tyx, next-gen CAR-T, TIG­IT an­ti­body and more

3 years ago
R&D

Cell ther­a­py biotech shifts fo­cus to UK, makes deep cuts to US head­count

3 years ago
People
R&D
First page Previous page 16171819202122 Next page Last page
A service from the Financial Times